Psychedelics Stella acquires Field Trip’s U.S. assets to enhance its psychedelic therapy offerings Stella closed a US$7 million funding round led by Sterling Partners last month Rowan DunneJune 28, 2023
Stock News Reunion Neuroscience struggles to maintain Nasdaq listing requirements The company has until mid-October to fulfill the requirements before the exchange takes further action Rowan DunneApril 26, 2023
Canada Field Trip facilitates beneficial psychedelic-assisted therapy for cancer patient Patient participated in ketamine and psilocybin sessions through the Special Access Program from Health Canada Rowan DunneSeptember 2, 2022
Stock News Reunion Neuroscience starts trading on the TSX Reunion still holds 21.84% interest in Field Trip Health & Wellness Rowan DunneAugust 17, 2022
Psychedelics Field Trip administers new synthetic molecule in Australia Initial dose of FT-104 given in Adelaide, company announces name change Rowan DunneJuly 22, 2022
Business Field Trip to split into two independent companies Current shareholders of the firm will receive shares of each company Natalia Buendia CalvilloMay 3, 2022
Business Field Trip Health opens clinic in Vancouver: Q&A with founder Ronan Levy The new facility will feature the firm's ketamine-assisted therapy program, as well as a range of health and lifestyle services Nick LabaDecember 8, 2021